Vivani Medical, Inc. (NASDAQ:VANI – Get Free Report) insider Donald Dwyer acquired 20,000 shares of the firm’s stock in a transaction on Thursday, November 12th. The shares were purchased at an average cost of $0.98 per share, for a total transaction of $19,600.00. Following the completion of the purchase, the insider directly owned 75,000 shares of the company’s stock, valued at approximately $73,500. The trade was a 36.36% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Vivani Medical Stock Performance
NASDAQ VANI opened at $1.01 on Monday. The firm has a market cap of $91.10 million, a price-to-earnings ratio of -3.16 and a beta of 2.51. The company has a 50 day moving average of $1.18 and a 200-day moving average of $1.24. Vivani Medical, Inc. has a 1-year low of $0.80 and a 1-year high of $1.66.
Vivani Medical (NASDAQ:VANI – Get Free Report) last posted its earnings results on Wednesday, November 11th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.01.
Wall Street Analysts Forecast Growth
Several equities analysts have issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vivani Medical in a research report on Friday, October 2nd. Wall Street Zen lowered Vivani Medical from a “hold” rating to a “sell” rating in a research note on Sunday. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $3.75.
View Our Latest Stock Analysis on Vivani Medical
Vivani Medical Company Profile
Vivani Medical is a clinical-stage medical technology company developing miniature, implantable devices designed to deliver medicines over extended periods. Its NanoPortal platform is intended to provide sustained drug delivery from a small implant placed under the skin, with the goal of reducing the need for frequent dosing. The company is advancing implant programs based on GLP-1 medicines for chronic conditions, including obesity and type 2 diabetes. These programs remain in development, and their availability and use depend on clinical and regulatory progress.
Featured Articles
- Five stocks we like better than Vivani Medical
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Vivani Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vivani Medical and related companies with MarketBeat.com's FREE daily email newsletter.
